The United Laboratories International Holdings Limited

中/EN
中文繁體 English
  • Investor Relations
    IR Home Corporate Overview Financial Highlights Financial Reports ESG Reports Regulatory Filings Press Releases Company Presentations Stock Quotes & Charts Analyst Coverage FAQs IR Contact
  • Corporate
Investor Relations
  • IR Home
  • Corporate Overview
  • Financial Highlights
  • Financial Reports
  • ESG Reports
  • Regulatory Filings
  • Press Releases
  • Company
    Presentations
  • Stock Quotes &
    Charts
  • Analyst Coverage
  • FAQs
  • IR Contact

Press Releases

2015
Please select
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
AUG
18
The United Laboratories International Holdings Limited Announces 2015 Interim Results, Profit from the Core Business Increased by 4.5% to Approximately HK$374.0 Million, Remarkable Sales Performance of Recombinant Human Insulin Injection Products, Steady Growth of Overseas Sales
MAR
31
The United Laboratories International Holdings Limited Announces 2014 Annual Results, Profit Attributable to Equity Holders Significantly Increased by 13.2 Times to HK$681 Million, Selling Prices of Intermediate and Bulk Medicine Products Continuously Increased Satisfactory Sales Performance of the Recombinant Human Insulin Products
Disclaimer | Sitemap

Copyright © 2019 The United Laboratories International Holdings Limited. All rights reserved.